Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
Recurrent Ovarian Epithelial Cancer
About this trial
This is an interventional treatment trial for Recurrent Ovarian Epithelial Cancer
Eligibility Criteria
Inclusion Criteria: Diagnosis of ovarian epithelial carcinoma Previously treated with an adequate course of platinum based chemotherapy Evidence of intraabdominal disease No significant adhesions Performance status - Zubrod 0-2 Lymphocyte count at least 500/mm^3 Bilirubin no greater than 1.5 mg/dL SGOT less than 2.5 times upper limit of normal Creatinine no greater than 1.5 mg/dL No major disorder of the cardiovascular system No major disorder of the pulmonary system Not pregnant or nursing Fertile patients must use effective contraception Successful placement of peritoneal catheter No overt autoimmune disease No concurrent chronic steroid therapy No prior radiotherapy Prior surgery allowed Recovered from prior therapy
Sites / Locations
- M D Anderson Cancer Center
Arms of the Study
Arm 1
Experimental
Treatment (ALVAC-hB7.1, recombinant interferon gamma)
Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.